Potential applications for biguanides in oncology

Journal of Clinical Investigation

Volumn 123, Issue 9, 2013, Pages 3693-3700

  Pollak, Michael ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIGUANIDE DERIVATIVE; INSULIN; METFORMIN; ORGANIC CATION TRANSPORTER 1; PHENFORMIN; PLACEBO; RESISTIN; SALICYLIC ACID; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BREAST CANCER; BREAST SURGERY; CANCER RESISTANCE; CANCER THERAPY; CELL TRANSFORMATION; COLON CANCER; COMPETITIVE INHIBITION; DNA DAMAGE; DNA REPAIR; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EXPOSURE; DRUG TARGETING; DRUG TRANSPORT; ENERGY CONSUMPTION; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; INSULIN RELEASE; LETHALITY; LIVER CELL; LOW DRUG DOSE; MELANOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PALLIATIVE THERAPY; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT DURATION;

ANTIMETABOLITES, ANTINEOPLASTIC; BIGUANIDES; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENERGY METABOLISM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84883542202     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI67232     Document Type: Review

References (95)

1. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11(5):325-337.
2. Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2012;2(9):778-790.
3. Turner N, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes. 2008;57(5):1414-1418.
4. Falcone AB, Mao RL, Shrago E. A study of the action of hypoglycemia-producing biguanide and sulfonylurea compounds on oxidative phosphorylation. J Biol Chem. 1962;237:904-909.
5. Ota S, et al. Metformin suppresses glucose-6-phosphatase expression by a complex I inhibition and AMPK activation-independent mechanism. Biochem Biophys Res Commun. 2009;388(2):311-316.
6. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348(pt 3):607-614. (Pubitemid 30410251)
7. El-Mir MY, Nogueira V, Fontaine E, Avéret N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275(1):223-228. (Pubitemid 30038975)
8. Ouyang J, Parakhia RA, Ochs RS. Metformin activates AMP kinase through inhibition of AMP deaminase. J Biol Chem. 2011;286(1):1-11.
9. Logie L, et al. Cellular responses to the metal-binding properties of metformin. Diabetes. 2012;61(6):1423-1433.
10. Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med. 2008;358(1):47-54.
11. Chen Ch, et al. Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013;74(5):e424-e330.
12. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304-1305. (Pubitemid 40813563)
13. Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer incidence and mortality: A meta-analysis. Cancer Epidemiol. 2013;37(3):207-218.
14. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One. 2012;7(3):e33411.
15. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167(4):492-499.
16. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care. 2012;35(12):2665-2673.
17. Nkontchou G, et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab. 2011;96(8):2601-2608.
18. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011;11:20.
19. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010;33(6):1304-1308.
20. Lega IC, Austin PC, Gruneir A, Goodwin PJ, Rochon PA, Lipscombe LL. Association between metformin therapy and mortality after breast cancer: a population-based study [published online ahead of print April 30, 2013]. Diabetes Care. doi:10.2337/dc12-2535.
21. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66(21):10269-10273. (Pubitemid 44799743)
22. Anisimov VN, et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol. 2005;40(8-9):685-693. (Pubitemid 41265819)
23. Dykens JA, Jamieson J, Marroquin L, Nadanaciva S, Billis PA, Will Y. Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. Toxicol Appl Pharmacol. 2008;233(2):203-210. (Pubitemid 50293339)
24. Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012;22(11):820-827.
25. Nies AT, Koepsell H, Damme K, Schwab M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol. 2011;(201):105-167.
26. Segal ED, Yasmeen A, Beauchamp MC, Rosenblatt J, Pollak M, Gotlieb WH. Relevance of the OCT1 transporter to the antineoplastic effect of biguanides. Biochem Biophys Res Commun. 2011;414(4):694-699.
27. Shaw RJ, et al. The kinase LKB1 mediates glucose homeostasis in liver therapeutic effects of metformin. Science. 2005;310(5754):1642-1646. (Pubitemid 41780780)
28. Foretz M, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010;120(7):2355-2369.
29. Pritchard KI, et al. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J Clin Oncol. 2011;29(29):3869-3876.
30. Goodwin PJ, et al. Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. J Clin Oncol. 2012;30(2):164-171.
31. Ma J, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst. 2004;96(7):546-553. (Pubitemid 38559579)
32. Wolpin BM, et al. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol. 2009;27(2):176-185.
33. Ma J, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008;9(11):1039-1047.
34. Venkateswaran V, et al. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst. 2007;99(23):1793-1800. (Pubitemid 351767208)
35. Ferguson RD, et al. Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res. 2012;14(1):R8.
36. Algire C, Amrein L, Bazile M, David S, Zakikhani M, Pollak M. Diet tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene. 2011;30(10):1174-1182.
37. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12(3):159-169.
38. Hvid H, et al. Stimulation of MC38 tumor growth by insulin analog X10 involves the serine synthesis pathway. Endocr Relat Cancer. 2012;19(4):557-574.
39. Pearce EL, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature. 2009;460(7251):103-107.
40. Moiseeva O, et al. Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation. Aging Cell. 2013;12(3):489-498.
41. Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci U S A. 2013;110(3):972-977.
42. Evia-Viscarra ML, et al. The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. J Pediatr Endocrinol Metab. 2012;25(1-2):41-49.
43. Gómez-Díaz RA, et al. Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial. Metabolism. 2012;61(9):1247-1255.
44. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013;494(7436):256-260.
45. Singh S, Akhtar N, Ahmad J. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study. Diabetes Metab Syndr. 2012;6(4):207-211.
46. Cabreiro F, et al. Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell. 2013;153(1):228-239.
47. Corominas-Faja B, et al. Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging (Albany NY). 2012;4(7):480-498.
48. Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature. 2012;491(7424):364-373.
49. Wallace DC. Mitochondria and cancer. Nat Rev Cancer. 2012;12(10):685-698.
50. Pollak M. Targeting oxidative phosphorylation: why, when, and how. Cancer Cell. 2013;23(3):263-264.
51. Hardie DG. The LKB1-AMPK pathway-friend or foe in cancer? Cancer Cell. 2013;23(2):131-132.
52. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13(4):251-262.
53. Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M. Metformin blocks the stimulative effect of a high energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid acid synthase. Endocr Relat Cancer. 2010;17(2):351-360.
54. Larsson O, et al. Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc Natl Acad Sci U S A. 2012;109(23):8977-8982.
55. Javeshghani S, et al. Carbon source myc expression influence the antiproliferative actions of metformin. Cancer Res. 2012;72(23):6257-6267.
56. Shackelford DB, et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell. 2013;23(2):143-158.
57. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 2009;23(5):537-548.
58. Hadad SM, et al. Histological evaluation of AMPK signalling in primary breast cancer. BMC Cancer. 2009;9:307.
59. Sanchez-Cespedes M, et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 2002;62(13):3659-3662. (Pubitemid 34728843)
60. Duivenvoorden WC, et al. Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo. Br J Cancer. 2013;108(2):327-333.
61. Wang PY, et al. Increased oxidative metabolism in the Li-Fraumeni syndrome. N Engl J Med. 2013;368(11):1027-1032.
62. Matoba S, et al. p53 regulates mitochondrial respiration. Science. 2006;312(5780):1650-1653. (Pubitemid 43902663)
63. Jones RG, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell. 2005;18(3):283-293. (Pubitemid 41350534)
64. + cell proliferation in pancreatic cancer and have anticancer action. PLoS One. 2013;8(5):e63969.
65. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, acts together with chemotherapy to block tumor growth prolong remission. Cancer Res. 2009;69(19):7507-7511.
66. Kalender A, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010;11(5):390-401.
67. Zoncu R, Bar-Peled L, Efeyan A, Wang S, Sancak Y, Sabatini DM. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science. 2011;334(6056):678-683.
68. Ben Sahra I, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011;71(13):4366- 4372.
69. Ben Sahra I, et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 2010;70(6):2465-2475.
70. Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev. 2004;18(11):1272-1282. (Pubitemid 38720595)
71. Affar el B, Shah RG, Dallaire AK, Castonguay V, Shah GM. Role of poly(ADP-ribose) polymerase in rapid intracellular acidification induced by alkylating DNA damage. Proc Natl Acad Sci U S A. 2002;99(1):245-250.
72. Martin MJ, Hayward R, Viros A, Marais R. Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov. 2012;2(4):344-355.
73. Haq R, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell. 2013;23(3):302-315.
74. Vazquez F, et al. PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell. 2013;23(3):287-301.
75. Gwinn DM, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008;30(2):214-226. (Pubitemid 351626684)
76. Hawley SA, et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science. 2012;336(6083):918-922.
77. Le Floch R, et al. CD147 subunit of lactate/H+ symporters MCT1 hypoxia-inducible MCT4 is critical for energetics growth of glycolytic tumors. Proc Natl Acad Sci U S A. 2011;108(40):16663-16668.
78. Lubik AA, et al. Insulin directly increases de novo steroidogenesis in prostate cancer cells. Endocr Relat Cancer. 2013;20(2):173-186.
79. Quaile MP, et al. Toxicity and toxicokinetics of metformin in rats. Toxicol Appl Pharmacol. 2010;243(3):340-347.
80. Vidon N, Chaussade S, Noel M, Franchisseur C, Huchet B, Bernier JJ. Metformin in the digestive tract. Diabetes Res Clin Pract. 1988;4(3):223-229. (Pubitemid 18080749)
81. Appleyard MV, et al. Phenformin as prophylaxis therapy in breast cancer xenografts. Br J Cancer. 2012;106(6):1117-1122.
82. Zhu Z, Jiang W, McGinley J, Thompson H. Comparison of of metformin, phenformin and buformin in mammary carcinogenesis in nonobese, non diabetic rats. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; April 6-10, 2013; Washington, DC. Abstract 2272.
83. Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature. 2012;485(7400):661-665.
84. NIH. ClinicalTrials.gov. NIH Web site. Accessed July 23, 2013.
85. Huang X, et al. Important role of the LKB1-AMPK pathway in suppressing tumourigenesis in PTEN deficient mice. Biochem J. 2008;412(2):211-221. (Pubitemid 351758227)
86. Hadad S, et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat. 2011;128(3):783-794.
87. Bonanni B, et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol. 2012;30(21):2593-2600.
88. Decensi A, et al. Lapatinib activity in premalignant lesions HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. Cancer Prev Res (Phila). 2011;4(8):1181-1189.
89. Decensi A, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst. 2003;95(11):779-790. (Pubitemid 36798424)
90. Niraula S, et al. Metformin in early breast cancer: A prospective, open-label, neoadjuvant window of opportunity study. Breast Cancer Res Treat. 2012;135(3):821-830.
91. Ellis MJ, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype - ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342-2349.
92. Hosono K, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila). 2010;3(9):1077-1083.
93. Blouin M, et al. Metformin and biomarkers relevant to neoplasia in nondiabetic patients [abstract e 14615]. J Clin Oncol. 2013;31(suppl).
94. Gontier E, et al. High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging. 2008;35(1):95-99. (Pubitemid 350234148)
95. Habibollahi P, van den Berg NS, Kuruppu D, Loda M, Mahmood U. Metformin - an adjunct antineoplastic therapy - divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging. J Nucl Med. 2013;54(2):252-258.